| Nome |
# |
|
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications, file e0ff0074-2c06-9bac-e053-1705fe0af019
|
763
|
|
The G Protein-Coupled Receptor GPR17: Overview and Update, file e0ff0072-b0e8-9bac-e053-1705fe0af019
|
450
|
|
GPR17 receptor modulators and their therapeutic implications: review of recent patents, file e0ff0074-a9fe-9bac-e053-1705fe0af019
|
375
|
|
Overview on Radiolabel-Free in Vitro Assays for GPCRs, file e0ff0072-ac8f-9bac-e053-1705fe0af019
|
298
|
|
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity, file e0ff0073-da3e-9bac-e053-1705fe0af019
|
294
|
|
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor, file e0ff0072-b2fb-9bac-e053-1705fe0af019
|
210
|
|
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor, file e0ff0073-08ff-9bac-e053-1705fe0af019
|
201
|
|
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity, file e0ff0073-b0d5-9bac-e053-1705fe0af019
|
188
|
|
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain, file e0ff0073-e005-9bac-e053-1705fe0af019
|
186
|
|
New sensible method to quantize the intestinal absorption of receptor ligands, file e0ff0073-da40-9bac-e053-1705fe0af019
|
180
|
|
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells, file e0ff0073-c789-9bac-e053-1705fe0af019
|
179
|
|
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia, file e0ff0074-474a-9bac-e053-1705fe0af019
|
107
|
|
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site, file e0ff0072-efd7-9bac-e053-1705fe0af019
|
106
|
|
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview, file e0ff0073-f268-9bac-e053-1705fe0af019
|
96
|
|
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7, file e0ff0072-c54b-9bac-e053-1705fe0af019
|
91
|
|
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists, file e0ff0074-415d-9bac-e053-1705fe0af019
|
90
|
|
The P2X7 Receptor in Infection and Inflammation, file e0ff0072-fbb1-9bac-e053-1705fe0af019
|
79
|
|
Emerging Roles of Purinergic Signaling in Diabetes, file e0ff0073-c301-9bac-e053-1705fe0af019
|
76
|
|
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists, file e0ff0073-eaed-9bac-e053-1705fe0af019
|
71
|
|
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists, file e0ff0074-415e-9bac-e053-1705fe0af019
|
70
|
|
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases, file e0ff0073-1410-9bac-e053-1705fe0af019
|
63
|
|
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents, file e0ff0073-9499-9bac-e053-1705fe0af019
|
63
|
|
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity, file e0ff0073-0c0b-9bac-e053-1705fe0af019
|
27
|
|
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents, file e0ff0073-0fb8-9bac-e053-1705fe0af019
|
16
|
|
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases, file 1b8ef5ed-7704-47fa-94d5-f5e9cbbfb953
|
15
|
|
I protocolli operativi nella violenza di genere, file e0ff0073-d0b7-9bac-e053-1705fe0af019
|
14
|
|
Pharmacological characterization of the GPR17 receptor dual profile, file e0ff0073-08ed-9bac-e053-1705fe0af019
|
13
|
|
Design and synthesis of novel thiazolo[5,4-d]pyrimidine derivatives with high affinity for both the adenosine a1 and a2a receptors, and efficacy in animal models of depression, file e0ff0074-dcba-9bac-e053-1705fe0af019
|
13
|
|
Machine Learning Scoring Functions for Drug Discovery from Experimental and Computer-Generated Protein-Ligand Structures: Towards Per-Target Scoring Functions, file ee751a8f-808f-49fe-98ac-904c1b3571f4
|
8
|
|
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects, file e0ff0072-b2d5-9bac-e053-1705fe0af019
|
7
|
|
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?, file e0ff0074-fba5-9bac-e053-1705fe0af019
|
6
|
|
A patent review of adenosine A2B receptor antagonists (2016-present), file 98ec94e8-7aff-4f03-aee8-17e3f5b17930
|
5
|
|
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents, file e0ff0074-9934-9bac-e053-1705fe0af019
|
5
|
|
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists, file e0ff0074-9ad4-9bac-e053-1705fe0af019
|
5
|
|
Combined therapy of A1AR agonists and A2AAR antagonists in neuroinflammation, file e0ff0074-e319-9bac-e053-1705fe0af019
|
5
|
|
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease, file e0ff0074-e372-9bac-e053-1705fe0af019
|
5
|
|
Letters in Drug Design & Discovery, file e0ff0072-f968-9bac-e053-1705fe0af019
|
4
|
|
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis, file e0ff0074-9ad2-9bac-e053-1705fe0af019
|
4
|
|
P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications, file e0ff0074-e31b-9bac-e053-1705fe0af019
|
4
|
|
4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives, file 902a4cf9-2271-4561-aad1-fd1d7dff1138
|
3
|
|
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction, file e0ff0072-5f55-9bac-e053-1705fe0af019
|
3
|
|
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines, file e0ff0072-8f11-9bac-e053-1705fe0af019
|
3
|
|
P2X7 Receptor as a Therapeutic Target, file e0ff0072-ba30-9bac-e053-1705fe0af019
|
3
|
|
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists, file e0ff0072-61d5-9bac-e053-1705fe0af019
|
2
|
|
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors, file e0ff0072-9bb8-9bac-e053-1705fe0af019
|
2
|
|
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor, file e0ff0072-aa02-9bac-e053-1705fe0af019
|
2
|
|
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype, file e0ff0072-e61e-9bac-e053-1705fe0af019
|
2
|
|
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases, file e0ff0073-1500-9bac-e053-1705fe0af019
|
2
|
|
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists, file 01f81285-1ef8-481b-9028-31f31ab25c15
|
1
|
|
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents, file 57cabbe3-043c-48bd-916a-f8e98fcb4a14
|
1
|
|
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases, file 59420ae7-5e97-4e1d-8aa4-2ee674ed2158
|
1
|
|
Molecular modeling study on potent and selective adenosine A3 receptor agonists., file e0ff0072-4db4-9bac-e053-1705fe0af019
|
1
|
|
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies, file e0ff0072-5fd3-9bac-e053-1705fe0af019
|
1
|
|
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation, file e0ff0072-61d4-9bac-e053-1705fe0af019
|
1
|
|
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists, file e0ff0072-61d6-9bac-e053-1705fe0af019
|
1
|
|
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine, file e0ff0072-b6e7-9bac-e053-1705fe0af019
|
1
|
|
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes, file e0ff0072-c151-9bac-e053-1705fe0af019
|
1
|
|
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA, file e0ff0073-14fe-9bac-e053-1705fe0af019
|
1
|
|
Development of novel pyridazinone-based adenosine receptor ligands, file e0ff0073-2923-9bac-e053-1705fe0af019
|
1
|
|
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor, file e0ff0073-8dda-9bac-e053-1705fe0af019
|
1
|
|
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor, file e0ff0074-5816-9bac-e053-1705fe0af019
|
1
|
|
New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity, file e0ff0074-a47d-9bac-e053-1705fe0af019
|
1
|
|
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity, file e0ff0074-dcbe-9bac-e053-1705fe0af019
|
1
|
|
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain, file e0ff0075-191e-9bac-e053-1705fe0af019
|
1
|
| Totale |
4.430 |